title: Protective effects of silymarin on fumonisin B₁-induced hepatotoxicity in mice.
abstract: The present study was conducted to investigate the effect of silymarin on experimental liver toxication induced by Fumonisin B₁1 (FB₁) in BALB/c mice. The mice were divided into six groups (n = 15). Group 1 served as the control. Group 2 was the silymarin control (100 mg/kg by gavage). Groups 3 and 4 were treated with FB₁ (Group 3, 1.5 mg/kg FB₁, intraperitoneally; and Group 4, 4.5 mg/kg FB₁). Group 5 received FB₁ (1.5 mg/kg) and silymarin (100 mg/kg), and Group 6 was given a higher dose of FB₁ (4.5 mg/kg FB₁) with silymarin (100 mg/kg). Silymarin treatment significantly decreased (p < 0.0001) the apoptotic rate. FB1 administration significantly increased (p < 0.0001) proliferating cell nuclear antigen and Ki-67 expression. Furthermore, FB1 elevated the levels of caspase-8 and tumor necrosis factor-alpha mediators while silymarin significantly reduced (p < 0.0001) the expression of these factors. Vascular endothelial growth factor (VEGF) and fibroblast growth factor-2 (FGF-2) expressions were significantly elevated in Group 4 (p < 0.0001). Silymarin administration alleviated increased VEGF and FGF-2 expression levels (p < 0.0001). In conclusion, silymarin ameliorated toxic liver damage caused by FB₁ in BALB/c mice.
authors.affiliation: Department of Pathology, Samsun, Faculty of Veterinary Medicine, University of Ondokuz Mayis, Samsun 55139, Turkey.msozmen@hotmail.com.
authors.forename: Mahmut
authors.initials: M
authors.lastname: Sozmen
authors.forename: Alparslan Kadir
authors.initials: AK
authors.lastname: Devrim
authors.forename: Recai
authors.initials: R
authors.lastname: Tunca
authors.forename: Murat
authors.initials: M
authors.lastname: Bayezit
authors.forename: Serpil
authors.initials: S
authors.lastname: Dag
authors.forename: Dinc
authors.initials: D
authors.lastname: Essiz
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000235:genetics / Q000378:metabolism; D037341:Fumonisins / Q000633:toxicity*; D005786:Gene Expression Regulation / Q000187:drug effects; D022781:Hepatocytes / Q000187:drug effects*; D019394:Ki-67 Antigen / Q000378:metabolism; D008099:Liver / Q000187:drug effects; D051379:Mice; D008807:Mice, Inbred BALB C; D009183:Mycotoxins / Q000633:toxicity*; D018919:Neovascularization, Physiologic / Q000187:drug effects; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism; D012838:Silymarin / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000378:metabolism
chemical_list: D000975:Antioxidants; D037341:Fumonisins; D019394:Ki-67 Antigen; D009183:Mycotoxins; D018809:Proliferating Cell Nuclear Antigen; D012838:Silymarin; D014409:Tumor Necrosis Factor-alpha; D042461:Vascular Endothelial Growth Factor A; D016222:Fibroblast Growth Factor 2; C056933:fumonisin B1
keywords: caspase-8; fibroblast growth factor-2; fumonisin B1; galectin-3; silymarin